MXPA03010341A - Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos. - Google Patents
Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.Info
- Publication number
- MXPA03010341A MXPA03010341A MXPA03010341A MXPA03010341A MXPA03010341A MX PA03010341 A MXPA03010341 A MX PA03010341A MX PA03010341 A MXPA03010341 A MX PA03010341A MX PA03010341 A MXPA03010341 A MX PA03010341A MX PA03010341 A MXPA03010341 A MX PA03010341A
- Authority
- MX
- Mexico
- Prior art keywords
- nep
- igs5
- combined
- disease
- concurrent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invencion se refiere al uso de un compuesto que tiene actividad inhibitoria, combinada en particular concurrente sobre la endopeptidasa neutra (EPN) y sobre una metaloproteasa novedosa designada IGS5, o una sal o un solvato farmaceuticamente aceptable o un ester biolabil del mismo, para la obtencion de un medicamento (composicion farmaceutica) para el tratamiento de mamiferos superiores, de preferencia el humano, que sufre de o que es susceptible de una enfermedad o sintoma la cual se puede aliviar o prevenir mediante la inhibicion de EPN y IGS5 combinada o cuncurrente. En un aspecto particular, la presente invencion se refiere al uso de los compuestos con actividad inhibitoria de EPN/IGS5 concurrente o combinada para el tratamiento de un mamifero superior, de preferencia un humano, que sufre de o es susceptible a una enfermedad o sintoma en donde los niveles de gran-ET-1 estan elevados y en el cual la enfermedad o el sintoma puede ser aliviada o prevenida por la inhibicion combinada o concurrente de MEP y IGS5. En un aspecto particular adicional la presente invencion se refiere al uso de compuestos con actividad inhibitoria de EPM/IGS5 combinada o concurrente para el tratamiento de un mamifero superior, de preferencia el humano, que sufre de o es susceptible a una enfermedad o sintoma en donde ET-1 esta sobre regulado significativamente y en el cual, la enfermedad o el sintoma se puede aliviar o prevenir mediante la inhibicion combinada O concurrente de EPN y IGS5. En la presente invencion, los compuestos con actividad inhibitoria de EPN/IGS5 combinada o concurrente preferiblemente s e usan para el tratamiento y/o la profilaxis de la hipertension, incluyendo formas secundarias de hipertension tales como la hipertension pulmonar o renal, fallas de corazon, angina de pecho, arritmia; infarto de miocardio, hipertrofia cardiaca, isquetnia cerebral, enfermedad vascular periferica, hemorragia subaracnoidal, enfermedades pulmonares obstructivas cronicas, (EPOC), asma, enfermedades renales, ateroesclerosis y enfermedades en cancer colorectal cancer de prostata, en mamiferos, de preferencia en humano, y mas preferiblemente en una sud-poblacion de pacientes que son susceptibles a una enfermedad o sintoma la cual puede ser aliviada o prevenida mediante la inhibicion combinada o concurrente de EPN y IGS5. Ademas, puede ser benefico para combinar adicionalmente los compuestos que muestran la actividad inhibitoria de EPN/IGS5 combinada que muestran la concurrente con otros inhibidores de metaloproteasa individual y/o combinada tal que los inhibidores EPN/IGS5, por ejemplo, con los inhibidores de ACE- y/o EPN separados y/o los inhibidores mezclados de estas metaloproteasas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112231 | 2001-05-18 | ||
| US29233701P | 2001-05-22 | 2001-05-22 | |
| PCT/EP2002/005259 WO2002094176A2 (en) | 2001-05-18 | 2002-05-14 | Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03010341A true MXPA03010341A (es) | 2004-03-10 |
Family
ID=32842671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03010341A MXPA03010341A (es) | 2001-05-18 | 2002-05-14 | Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040162345A1 (es) |
| EP (1) | EP1397141A2 (es) |
| JP (1) | JP2004536063A (es) |
| CN (1) | CN1520299A (es) |
| AR (1) | AR039352A1 (es) |
| BR (1) | BR0209855A (es) |
| CA (1) | CA2447598A1 (es) |
| CZ (1) | CZ20033183A3 (es) |
| HU (1) | HUP0400988A3 (es) |
| MX (1) | MXPA03010341A (es) |
| PL (1) | PL367093A1 (es) |
| RU (1) | RU2003136077A (es) |
| SK (1) | SK14102003A3 (es) |
| WO (1) | WO2002094176A2 (es) |
| ZA (1) | ZA200308098B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784327B2 (en) | 1999-11-19 | 2006-03-09 | Abbvie B.V. | Human enzymes of the metalloprotease family |
| WO2004010106A2 (en) * | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| WO2005067937A1 (en) * | 2004-01-12 | 2005-07-28 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
| US7232813B2 (en) | 2004-01-12 | 2007-06-19 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| EP1753432A1 (en) * | 2004-05-14 | 2007-02-21 | Solvay Pharmaceuticals GmbH | Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| EP1776095A1 (en) * | 2004-06-23 | 2007-04-25 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
| US7816347B2 (en) | 2004-12-15 | 2010-10-19 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors |
| BRPI0608184A2 (pt) * | 2005-02-18 | 2009-11-17 | Solvay Pharm Gmbh | composições farmacêuticas compreendendo inibidores da nep, inibidores da nep, inibidores do sistema de produção de endotelina endógena e diuréticos |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| KR101970505B1 (ko) * | 2012-12-26 | 2019-04-19 | (주)아모레퍼시픽 | 멜라닌 형성 억제제를 함유하는 미백용 피부 외용제 조성물 |
| MD3259253T2 (ro) | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| TWI789401B (zh) | 2017-07-07 | 2023-01-11 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| RU2020110366A (ru) * | 2017-08-15 | 2021-09-16 | Инфлазоум Лимитед | Новые соединения сульфонамидкарбоксамидов |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| UY37847A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| CA2096418C (en) * | 1990-11-26 | 2001-11-20 | Philip J. Barr | Expression of pace in host cells and methods of use thereof |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US20020086405A1 (en) * | 2000-09-25 | 2002-07-04 | Inmaculada Silos-Santiago | 56638, a novel human neprilysin protease and uses thereof |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| JP2001275687A (ja) * | 2000-04-04 | 2001-10-09 | Masafumi Matsuo | 膜結合型メタロプロテアーゼ及びその可溶性分泌型 |
| US6991916B2 (en) * | 2000-07-14 | 2006-01-31 | Pfizer Inc. | Compounds for the treatment of sexual dysfunction |
| GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20030119714A1 (en) * | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-05-14 PL PL02367093A patent/PL367093A1/xx not_active Application Discontinuation
- 2002-05-14 EP EP02743004A patent/EP1397141A2/en not_active Withdrawn
- 2002-05-14 CZ CZ20033183A patent/CZ20033183A3/cs unknown
- 2002-05-14 WO PCT/EP2002/005259 patent/WO2002094176A2/en not_active Application Discontinuation
- 2002-05-14 BR BR0209855-5A patent/BR0209855A/pt not_active IP Right Cessation
- 2002-05-14 CA CA002447598A patent/CA2447598A1/en not_active Abandoned
- 2002-05-14 HU HU0400988A patent/HUP0400988A3/hu unknown
- 2002-05-14 CN CNA028101545A patent/CN1520299A/zh active Pending
- 2002-05-14 SK SK1410-2003A patent/SK14102003A3/sk unknown
- 2002-05-14 RU RU2003136077/15A patent/RU2003136077A/ru not_active Application Discontinuation
- 2002-05-14 AR ARP020101765A patent/AR039352A1/es not_active Application Discontinuation
- 2002-05-14 JP JP2002590897A patent/JP2004536063A/ja not_active Withdrawn
- 2002-05-14 MX MXPA03010341A patent/MXPA03010341A/es not_active Application Discontinuation
-
2003
- 2003-10-17 ZA ZA200308098A patent/ZA200308098B/en unknown
- 2003-11-18 US US10/715,112 patent/US20040162345A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1397141A2 (en) | 2004-03-17 |
| ZA200308098B (en) | 2004-10-18 |
| US20040162345A1 (en) | 2004-08-19 |
| AR039352A1 (es) | 2005-02-16 |
| RU2003136077A (ru) | 2005-08-10 |
| HUP0400988A2 (hu) | 2004-08-30 |
| CZ20033183A3 (cs) | 2004-07-14 |
| SK14102003A3 (sk) | 2004-08-03 |
| CN1520299A (zh) | 2004-08-11 |
| CA2447598A1 (en) | 2002-11-28 |
| HUP0400988A3 (en) | 2006-07-28 |
| WO2002094176A2 (en) | 2002-11-28 |
| JP2004536063A (ja) | 2004-12-02 |
| BR0209855A (pt) | 2004-06-15 |
| WO2002094176A3 (en) | 2003-12-11 |
| PL367093A1 (en) | 2005-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010341A (es) | Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos. | |
| KR100984939B1 (ko) | 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물 | |
| KR20070102544A (ko) | 유기 화합물의 조합물 | |
| Bane Jr et al. | Factor XI as a target for antithrombotic therapy | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| AU3664401A (en) | Platelet adp receptor inhibitors | |
| WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
| US20110046119A1 (en) | Therapeutic treatment | |
| CN103242310A (zh) | 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途 | |
| EA200500096A1 (ru) | Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| KR101261077B1 (ko) | 혈전증 치료제 | |
| AU2017203028A1 (en) | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors | |
| Buczko et al. | -Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. | |
| AU2016280058B2 (en) | Thromboxane receptor antagonists | |
| US20080032952A1 (en) | Combination Therapies Employing Nicotinic Acid Derivatives or Fibric Acid Derivatives | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
| WO2004045530A3 (en) | Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors | |
| PT97807A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo um inibidor da enzima de conversao da angiotensina utilizadas para prevenir a manisfestacao de reetenose apos angioplastia | |
| Cross | Antithrombotic agents | |
| Nagy | 24-HOUR AMBULATORY BLOOD PRESSURE REDUCTION WITH A PERINDOPRIL/AMLODIPINE FIXED-DOSE COMBINATION: PP. 15.427 | |
| CN116850173A (zh) | 一种二氢杨梅素在制备凝血X因子FXa抑制剂的药物中的应用 | |
| JP6364362B2 (ja) | ヒトキマーゼ阻害剤および機能性食品、並びにヒトキマーゼの活性を阻害する方法 | |
| Popescu | BLOOD PRESSURE LOWERING RESPONSE, CARDIAC REMODELING AND DIASTOLIC FUNCTION WITH THE FIXED LOW-DOSE COMBINATION PERINDOPRIL/INDAPAMIDE IN 300 NEVER TREATED ROMANIAN HYPERTENSIVE PATIENTS: PP. 15.428 | |
| Orynchak et al. | THE INFLUENCE OFTELMISARTAN IN COMBINATION WITHTORASEMIDE AND ATORVASTATIN ON THE CARDIOVASCULAR RISK FACTORS IN HYPERTENSIVES WITH HEART FAILURE: PP. 15.429 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |